An Open-Label, Randomized, 4-Period Crossover Study to Determine the Relative Bioavailability of the Phase 3 SYR-322 Tablets (12.5 and 25 mg) and Pioglitazone (15 and 45 mg) When Administered as Commercial Tablets and as a Combination Product

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.